<DOC>
	<DOCNO>NCT01504165</DOCNO>
	<brief_summary>This open-label , non-randomized , parallel-group , mono-center , single intravenous dose , Phase I trial investigate Pharmacokinetic ( PK ) safety cilengitide subject different grade renal impairment compare subject normal renal function .</brief_summary>
	<brief_title>Pharmacokinetics Subjects With Renal Impairment</brief_title>
	<detailed_description>Subjects impair renal function screen stratify estimate glomerular filtration rate ( GFR ) accord Modification Diet Renal Disease ( MDRD ) equation assign one stratification group define : Group Number/Renal function/Creatinine Clearance ( GFR accord MDRD ) 1 . Normal renal function ( ≥ 90 mL/min ) 2 . Mild renal impairment ( 60 - 89 mL/min ) 3 . Moderate renal impairment ( 30 - 59 mL/ min ) 4a : Severe renal impairment ( &lt; 30 mL/min ) - dialysis require 4b : ( applicable ) Severe renal impairment ( &lt; 30 mL/min ) - dialysis required Subjects Groups 2 3 receive single dose 2000mg cilengitide 1-hour i.v . infusion . Subjects group 4a receive single dose 1000mg cilengitide 1-hour i.v . infusion . PK sample collect basic PK parameter calculate . The safety , tolerability , PK evaluate Safety Monitoring Committee ( SMC ) . If SMC concern , Group 4b treat high dose ( 2000mg ) cilengitide . Then , Group 1 ( healthy subject ) start last subject renal impairment ( either Group 2 , 3 , 4a ; Group 4b , applicable ) complete activity Day 3 . They also receive single dose 2000mg cilengitide 1-hour i.v . infusion . The duration trial first subject enrol last subject last visit approximately 6 month ( approximately 8 month , case Group 4b include ) . Each subject participate trial 35 day , include screen end trial examination .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Body mass index ( BMI ) : ≥ 18 kg/m² ≤ 35 kg/m² For subject normal renal function : Vital sign ( pulse rate blood pressure ) within normal range show clinically relevant deviation Estimated creatinine clearance accord MDRD equation ≥ 90 mL/min Screening For subject impaired renal function : Laboratory parameter within acceptable range subject renal impairment , Vital sign : Pulse rate within normal range 45100 beats/minute supine position 5 minute rest . Blood pressure diastolic 100 mmHg , systolic 160 mmHg Groups 13 180 mmHg Group 4a 4b , supine position 5 minute rest Calculated creatinine clearance accord MDRD equation &lt; 90 mL/min Screening possibility stratification one Groups . History malignant disease within last 5 year acute malignant disease Medical history wound heal problem and/or current open wound Current history bleeding disorder and/or history thromboembolic event ( consider family history well ) ; thrombolytic oral parenteral anticoagulant within 30 day prior Day 1 Electrocardiogram recording ( 12lead ECG ) sign clinically relevant pathology judge Investigator For subject impaired renal function : Chronic heart failure non stabilize ( New York Heart Association [ NYHA ] class III IV ) Acute renal failure etiology ( include viral , toxic , drug induce ) Requiring dialysis History renal transplantation Uncontrolled diabetes mellitus judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Renal impairment</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>cilengitide</keyword>
	<keyword>subject mild</keyword>
	<keyword>moderate severe renal impairment compare subject normal renal function</keyword>
</DOC>